IL4I1 inhibitors and methods of use

Patent metadata

Field	Value
Publication number	US-12454525-B2
Application number	US-202117920850-A
Country	US
Kind code	B2
Filing date	May 4, 2021
Priority date	May 6, 2020
Publication date	Oct 28, 2025
Grant date	Oct 28, 2025

Abstract

Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

First claim

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, having the Formula Ia

wherein,
A is aryl;
L is a straight or branched (C 1 -C 5 ) alkylenyl, wherein one or more —CH 2 — groups in L are optionally and independently replaced with a moiety selected from the group consisting of O, and NH;
each occurrence of R 1 is independently halogen, C 1 -C 6 alkyl, or cycloheteroalkyl;
each occurrence of R 2 is independently

R 3 is hydrogen, C 1 -C 6 alkyl or haloC 1 -C 6 alkyl;
m is 0, 1 or 2; and
n is 1, 2 or 3.

2. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein L is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 O—, or —CHCH 3 —.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is phenyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2 and R 1 is fluorine, chlorine, pyrrolidine, methyl or ethyl.

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen, methyl or difluoromethyl.

7. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 1 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

10. A compound having the following structure

11. A compound having the following structure

or a pharmaceutically acceptable salt thereof.

12. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 11 , or pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.

15. A compound having the following structure

16. A compound having the following structure

or a pharmaceutically acceptable salt thereof.

17. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 16 , or pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound of claim 16 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier.

20. A compound having the following structure

21. A compound having the following structure

or a pharmaceutically acceptable salt thereof.

22. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 21 , or pharmaceutically acceptable salt thereof.

23. A pharmaceutical composition comprising a compound of claim 21 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition comprising a compound of claim 20 and a pharmaceutically acceptable carrier.

25. A compound selected from:

Assignees

• Merck Sharp & Dohme Llc

Inventors

• Cash Brandon D
• Fu Wenlang
• Giambasu George Madalin
• Haidle Andrew M
• Hopkins Brett A
• Larsen Matthew A
• Lesburg Charles A
• Liu Ping
• Mcgowan Meredeth A
• Pu Qinglin
• Sanyal Sulagna
• Siliphaivanh Phieng
• White Catherine M
• Yan Xin

Classifications

• C07D495/04

  Ortho-condensed systems · CPC title

• C07D419/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D417/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D413/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D409/14

  containing three or more hetero rings · CPC title